Home / Recalls / Central Admixture Pharmacy Services, Inc. / D-1012-2023

D-1012-2023 Class II Terminated

Recalled by Central Admixture Pharmacy Services, Inc. — Phoenix, AZ

FDA drug recall D-1012-2023 was initiated by Central Admixture Pharmacy Services, Inc. on July 14, 2023 and is designated Class II. Reason for recall: Lack of assurance of sterility. Validation data for decontamination cycles is lacking. The recall status is terminated (terminated March 28, 2025). Affected quantity: 33,073 bags.

Recall Details

Product Type
Drugs
Report Date
August 9, 2023
Initiation Date
July 14, 2023
Termination Date
March 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
33,073 bags

Product Description

oxyTOCIN 30 units added to Lactated Ringer's 500 mL, IV Bag, Rx only, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-6039-1

Reason for Recall

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Distribution Pattern

Nationwide in the USA

Code Information

Lot: 36-247353, Exp. 7/13/2023; 36-247260, 36-247261, 36-247262, Exp. 7/14/2023; 36-248215, 36-248218, 36-248222, Exp. 7/19/2023; 36-248861, 36-248862, 36-248863, 36-248865, Exp. 7/21/2023; 36-249513, 36-249514, 36-249659, 36-249693, Exp. 7/24/2023; 36-249661, 36-249662, 36-249663, 36-249664, 36-249665, Exp. 7/26/2023; 36-249750, 36-249754, 36-249755, 36-249756, 36-249757, Exp. 7/27/2023; 36-249995, 36-249996, 36-249997, 36-249999, 36-250001, 36-250003, 36-250230, Exp. 7/28/2023; 36-250424, 36-250425, 36-250426, 36-250427, 36-250428, 36-250429, Exp. 7/29/2023; 36-251374, 36-251375, 36-251376, 36-251377, 36-251378, 36-251379, 36-251380, 36-251381, 36-251382, Exp. 8/2/2023; 36-251438, 36-251441, 36-251442, Exp. 8/3/2023; 36-251799, 36-251801, 36-251802, 36-251803, 36-251805, 36-251806, 36-251804, Exp. 8/4/2023; 36-251993, 36-251995, 36-251996, Exp. 8/5/2023; 36-252202, Exp. 8/6/2023; 36-252470, 36-252474, 36-252476, 36-252477, 36-252478, Exp. 8/9/2023; 36-254387, 36-254388, 36-254389, 36-254390, 36-254391, 36-254392, 36-254393, 36-254398, 36-254399, Exp. 8/10/2023; 36-254666, 36-254807, Exp. 8/11/2023

Other recalls by Central Admixture Pharmacy Services, Inc.

  • D-0740-2026 Class III — Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient speci (July 16, 2026)
  • D-0618-2026 Class II — Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient speci (June 2, 2026)
  • D-0272-2025 Class I — PHENYLephrine added to 0.9% sodium chloride, 40 mg/250 mL* (160 mcg/mL), Rx Only (February 20, 2025)
  • D-0013-2024 Class II — fentaNYL in 0.9% sodium chloride, 2,500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx (September 21, 2023)
  • D-0028-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, (September 21, 2023)
  • D-0016-2024 Class II — fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volu (September 21, 2023)
  • D-0018-2024 Class II — midazolam in dextrose 5%, 50 mg/50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Centra (September 21, 2023)
  • D-0009-2024 Class II — fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx onl (September 21, 2023)
  • D-0027-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, R (September 21, 2023)
  • D-0020-2024 Class II — fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Repackaged by CAPS I (September 21, 2023)

FDA data resources